{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:51:16Z","timestamp":1793645476114,"version":"4.5.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"1.3.5 Project of High Altitude Medicine of West China Hospital, Sichuan University","award":["No. GYYX24003"],"award-info":[{"award-number":["No. GYYX24003"]}]},{"name":"\u201cQimingxing\u201d Research Fund for Young Talents of West China Hospital, Sichuan University","award":["No.HXQMX0101"],"award-info":[{"award-number":["No.HXQMX0101"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370192"],"award-info":[{"award-number":["82370192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2026NSFSC0677"],"award-info":[{"award-number":["No. 2026NSFSC0677"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02647-0","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T23:43:59Z","timestamp":1774223039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biomarker-empowered precision navigation of CAR-T cell therapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuru","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21:194. https:\/\/doi.org\/10.1186\/s12943-022-01663-0.","journal-title":"Mol Cancer"},{"key":"2647_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","volume":"15","author":"V Prasad","year":"2018","unstructured":"Prasad V, Immunotherapy. Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15:11\u20132. https:\/\/doi.org\/10.1038\/nrclinonc.2017.156.","journal-title":"Nat Rev Clin Oncol"},{"key":"2647_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-025-3061-8","author":"S Han","year":"2026","unstructured":"Han S, Yue J, Zheng H, Huang Y, Kong D, Wei G, et al. Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions. Sci China Life Sci. 2026. https:\/\/doi.org\/10.1007\/s11427-025-3061-8.","journal-title":"Sci China Life Sci"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell Elsevier BV. 2025;43:665\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019.","journal-title":"Cancer Cell Elsevier BV"},{"key":"2647_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales M-A, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management. Lancet Haematol. 2024;11:e459\u201370. https:\/\/doi.org\/10.1016\/S2352-3026(24)00077-2.","journal-title":"Lancet Haematol"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Mor\u00e1n-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:180. https:\/\/doi.org\/10.1038\/s41408-024-01167-8.","journal-title":"Blood Cancer J"},{"key":"2647_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.947","author":"S Irfan","year":"2025","unstructured":"Irfan S, Ayoobkhan FS, Vojjala N, Qureshi R, Rahman R, Kamboj I, et al. Immune effector cell-associated HLH-like syndrome (IEC-HS) in CAR-T and TCE-treated myeloma and B-cell malignancies: Insights from a pharmacovigilance study. Transpl Cell Ther [Internet]. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.947. [cited 2026 Jan 18].","journal-title":"Transpl Cell Ther [Internet]"},{"key":"2647_CR10","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales M-A, Cordas dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin cancer res : off j Am Assoc Cancer Res. 2024;30:4690\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1798.","journal-title":"Clin cancer res : off j Am Assoc Cancer Res"},{"key":"2647_CR11","doi-asserted-by":"publisher","unstructured":"I Z, L E-A, K F, V M-A, M D-B MJ et al. CAR-T cell therapy for cancer: Current challenges and future directions. Signal Transduction Targeted Ther [Internet]. Signal Transduct Target Ther; 2025;10. https:\/\/doi.org\/10.1038\/s41392-025-02269-w. Cited 12 Mar 2026.","DOI":"10.1038\/s41392-025-02269-w"},{"key":"2647_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","volume":"8","author":"M Du","year":"2020","unstructured":"Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomark Res. 2020;8:13. https:\/\/doi.org\/10.1186\/s40364-020-00190-8.","journal-title":"Biomark Res"},{"key":"2647_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","volume":"31","author":"SS Raj","year":"2025","unstructured":"Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA, et al. An inflammatory biomarker signature of response to CAR-T cell therapy in non-hodgkin lymphoma. Nat Med. 2025;31:1183\u201394. https:\/\/doi.org\/10.1038\/s41591-025-03532-x.","journal-title":"Nat Med"},{"key":"2647_CR14","doi-asserted-by":"publisher","first-page":"1169071","DOI":"10.3389\/fimmu.2023.1169071","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071. https:\/\/doi.org\/10.3389\/fimmu.2023.1169071.","journal-title":"Front Immunol"},{"key":"2647_CR15","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513. https:\/\/doi.org\/10.1182\/blood.2020010543.","journal-title":"Blood"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"R K","year":"2023","unstructured":"K R, Dk H, Jm RBPSSA. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol J Hematol Oncol. 2023;16:88. https:\/\/doi.org\/10.1186\/s13045-023-01465-x.","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"2647_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398. https:\/\/doi.org\/10.1038\/s41577-020-00490-y.","journal-title":"Nat Rev Immunol"},{"key":"2647_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297.","journal-title":"Cancer Immunol Res"},{"key":"2647_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/bloodadvances.2021006563","volume":"7","author":"E Bourbon","year":"2023","unstructured":"Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, et al. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2023;7:744\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2021006563.","journal-title":"Blood Adv"},{"key":"2647_CR20","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1182\/blood-2019-131041","volume":"134","author":"MD Jain","year":"2019","unstructured":"Jain MD, Zhao H, Atkins R, Menges MA, Pope CR, Faramand R, et al. Tumor inflammation and myeloid derived suppressor cells reduce the efficacy of CD19 CAR T cell therapy in lymphoma. Blood Am Soc Hematol. 2019;134:2885\u20132885. https:\/\/doi.org\/10.1182\/blood-2019-131041.","journal-title":"Blood Am Soc Hematol"},{"key":"2647_CR21","doi-asserted-by":"publisher","first-page":"1362133","DOI":"10.3389\/fimmu.2024.1362133","volume":"15","author":"P-F Zhang","year":"2024","unstructured":"Zhang P-F, Xie D. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: A new hope? Front Immunol. 2024;15:1362133. https:\/\/doi.org\/10.3389\/fimmu.2024.1362133.","journal-title":"Front Immunol"},{"key":"2647_CR22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert M-L, Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29:906\u201316. https:\/\/doi.org\/10.1038\/s41591-023-02234-6.","journal-title":"Nat Med"},{"key":"2647_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/2159-8290.CD-24-1230","volume":"15","author":"L Marcos-Kovandzic","year":"2025","unstructured":"Marcos-Kovandzic L, Avagliano M, Ben Khelil M, Srikanthan J, Abdallah R, Petrocelli V, et al. Gut microbiota modulation through akkermansia spp. Supplementation increases CAR T-cell potency. Cancer Discov. 2025;15:1905\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1230.","journal-title":"Cancer Discov"},{"key":"2647_CR24","doi-asserted-by":"publisher","first-page":"42774","DOI":"10.1038\/s41598-025-27061-2","volume":"15","author":"D Carbonell","year":"2025","unstructured":"Carbonell D, Rodr\u00edguez-Sosa A, G\u00f3mez-Serrano L, P\u00e9rez-Corral A, Ruano G, Galayo M, et al. Predictive biomarkers validation of CD3\u2009+\u2009cell apheresis yield in CAR-T manufacturing for diffuse large B-cell lymphoma: A machine learning approach. Sci Rep. 2025;15:42774. https:\/\/doi.org\/10.1038\/s41598-025-27061-2.","journal-title":"Sci Rep"},{"key":"2647_CR25","doi-asserted-by":"publisher","first-page":"780442","DOI":"10.3389\/fimmu.2021.780442","volume":"12","author":"PH Mehta","year":"2021","unstructured":"Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front Immunol. 2021;12:780442. https:\/\/doi.org\/10.3389\/fimmu.2021.780442.","journal-title":"Front Immunol"},{"key":"2647_CR26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cells9051225","volume":"9","author":"F Korell","year":"2020","unstructured":"Korell F, Laier S, Sauer S, Veelken K, Hennemann H, Schubert M-L, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL. Cells. 2020;9:1225. https:\/\/doi.org\/10.3390\/cells9051225.","journal-title":"Cells"},{"key":"2647_CR27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/ijms27020866","volume":"27","author":"I de la Garc\u00eda","year":"2026","unstructured":"de la Garc\u00eda I, Garc\u00eda-Hoz C, Martin-Moro F, Fern\u00e1ndez-Velasco JI, Vel\u00e1zquez-Kennedy K, Rodr\u00edguez-Mart\u00edn E, et al. Apheresis CD8\u2009+\u2009CCR7+CD45RA \u2013 T-cells as a novel biomarker associated with CAR T-cell kinetics and clinical outcome. Int J Mol Sci. 2026;27:866. https:\/\/doi.org\/10.3390\/ijms27020866.","journal-title":"Int J Mol Sci"},{"key":"2647_CR28","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022;132:e150807. https:\/\/doi.org\/10.1172\/JCI150807.","journal-title":"J Clin Invest"},{"key":"2647_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"key":"2647_CR30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129:2123\u201332. https:\/\/doi.org\/10.1172\/JCI125423.","journal-title":"J Clin Invest"},{"key":"2647_CR31","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations. Clin Transl Immunol. 2019;8:e1049. https:\/\/doi.org\/10.1002\/cti2.1049.","journal-title":"Clin Transl Immunol"},{"key":"2647_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340. https:\/\/doi.org\/10.1016\/j.cell.2017.01.016.","journal-title":"Cell"},{"key":"2647_CR33","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","volume":"96","author":"T Brocker","year":"2000","unstructured":"Brocker T. Chimeric fv-zeta or fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96:1999\u20132001.","journal-title":"Blood"},{"key":"2647_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715\u201327. https:\/\/doi.org\/10.1038\/s41571-021-00530-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2647_CR35","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354. https:\/\/doi.org\/10.1038\/s41591-022-01969-y.","journal-title":"Nat Med"},{"key":"2647_CR36","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas. Mol Ther: J Am Soc Gene Ther. 2018;26:2727\u201337. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.009.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"2647_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli E, Bellesi S, Pansini I, Di Cesare G, Iacovelli C, Malafronte R, et al. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br J Haematol. 2023;203:564\u201370. https:\/\/doi.org\/10.1111\/bjh.19117.","journal-title":"Br J Haematol"},{"key":"2647_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1189\/jlb.5HI0716-322RR","volume":"102","author":"P Guha","year":"2017","unstructured":"Guha P, Cunetta M, Somasundar P, Espat NJ, Junghans RP, Katz SC. Frontline science: Functionally impaired geriatric CAR-T cells rescued by increased \u03b15\u03b21 integrin expression. J Leukoc Biol. 2017;102:201\u20138. https:\/\/doi.org\/10.1189\/jlb.5HI0716-322RR.","journal-title":"J Leukoc Biol"},{"key":"2647_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: Metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13:66. https:\/\/doi.org\/10.1186\/s40164-024-00535-1.","journal-title":"Exp Hematol Oncol"},{"key":"2647_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Si X, Shao M, Teng X, Xiao G, Huang H. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 2022;15:38. https:\/\/doi.org\/10.1186\/s13045-022-01255-x.","journal-title":"J Hematol Oncol"},{"key":"2647_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","volume":"23","author":"M Sukumar","year":"2016","unstructured":"Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab. 2016;23:63\u201376. https:\/\/doi.org\/10.1016\/j.cmet.2015.11.002.","journal-title":"Cell Metab"},{"key":"2647_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.celrep.2019.03.037","volume":"27","author":"L DeVorkin","year":"2019","unstructured":"DeVorkin L, Pavey N, Carleton G, Comber A, Ho C, Lim J, et al. Autophagy regulation of metabolism is required for CD8\u2009+\u2009T cell anti-tumor immunity. Cell Rep. 2019;27:502\u2013e5135. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.037.","journal-title":"Cell Rep"},{"key":"2647_CR43","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","volume":"21","author":"Y-R Yu","year":"2020","unstructured":"Yu Y-R, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. Disturbed mitochondrial dynamics in CD8\u2009+\u2009TILs reinforce T cell exhaustion. Nat Immunol. 2020;21:1540\u201351. https:\/\/doi.org\/10.1038\/s41590-020-0793-3.","journal-title":"Nat Immunol"},{"key":"2647_CR44","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cpt.2040","volume":"109","author":"C Liu","year":"2021","unstructured":"Liu C, Ayyar VS, Zheng X, Chen W, Zheng S, Mody H, et al. Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans. Clin Pharmacol Ther. 2021;109:716\u201327. https:\/\/doi.org\/10.1002\/cpt.2040.","journal-title":"Clin Pharmacol Ther"},{"key":"2647_CR45","doi-asserted-by":"publisher","first-page":"114421","DOI":"10.1016\/j.addr.2022.114421","volume":"188","author":"T Qi","year":"2022","unstructured":"Qi T, McGrath K, Ranganathan R, Dotti G, Cao Y. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Adv Drug Deliv Rev. 2022;188:114421. https:\/\/doi.org\/10.1016\/j.addr.2022.114421.","journal-title":"Adv Drug Deliv Rev"},{"key":"2647_CR46","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415.","journal-title":"Sci Transl Med"},{"key":"2647_CR47","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","volume":"60","author":"K Ogasawara","year":"2021","unstructured":"Ogasawara K, Dodds M, Mack T, Lymp J, Dell\u2019Aringa J, Smith J. Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma. Clin Pharmacokinet. 2021;60:1621\u201333. https:\/\/doi.org\/10.1007\/s40262-021-01039-5.","journal-title":"Clin Pharmacokinet"},{"key":"2647_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet (lond Engl). 2021;398:491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet (lond Engl)"},{"key":"2647_CR49","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/cancers13112782","volume":"13","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, K\u00fcnkele A, Huisinga W, et al. Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model. Cancers. 2021;13:2782. https:\/\/doi.org\/10.3390\/cancers13112782.","journal-title":"Cancers"},{"key":"2647_CR50","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.015.","journal-title":"Mol Ther"},{"key":"2647_CR51","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther: J Am Soc Gene Ther. 2016;24:1135\u201349. https:\/\/doi.org\/10.1038\/mt.2016.63.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"2647_CR52","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv. 2020;4:560\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2019000525.","journal-title":"Blood Adv"},{"key":"2647_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih A, Voillet V, Hanafi L-A, DeBerg HA, Yajima M, Hawkins R, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11:219. https:\/\/doi.org\/10.1038\/s41467-019-13880-1.","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"2647_CR54","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1002\/jcph.1691","volume":"60","author":"A Chaudhury","year":"2020","unstructured":"Chaudhury A, Zhu X, Chu L, Goliaei A, June CH, Kearns JD, et al. Chimeric antigen receptor T cell therapies: A review of cellular kinetic-pharmacodynamic modeling approaches. J Clin Pharmacol. 2020;60(Suppl 1):S147\u201359. https:\/\/doi.org\/10.1002\/jcph.1691.","journal-title":"J Clin Pharmacol"},{"key":"2647_CR55","doi-asserted-by":"publisher","first-page":"20210229","DOI":"10.1098\/rspb.2021.0229","volume":"288","author":"GJ Kimmel","year":"2021","unstructured":"Kimmel GJ, Locke FL, Altrock PM. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. Proc Biol Sci. 2021;288:20210229. https:\/\/doi.org\/10.1098\/rspb.2021.0229.","journal-title":"Proc Biol Sci"},{"key":"2647_CR56","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.1235454","volume":"340","author":"VR Buchholz","year":"2013","unstructured":"Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Gr\u00e4f P, et al. Disparate individual fates compose robust CD8\u2009+\u2009T cell immunity. Science. 2013;340:630\u20135. https:\/\/doi.org\/10.1126\/science.1235454.","journal-title":"Science"},{"key":"2647_CR57","doi-asserted-by":"publisher","first-page":"13540","DOI":"10.1038\/ncomms13540","volume":"7","author":"JM Marchingo","year":"2016","unstructured":"Marchingo JM, Prevedello G, Kan A, Heinzel S, Hodgkin PD, Duffy KR. T-cell stimuli independently sum to regulate an inherited clonal division fate. Nat Commun. 2016;7:13540. https:\/\/doi.org\/10.1038\/ncomms13540.","journal-title":"Nat Commun"},{"key":"2647_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ. Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384:673\u20134. https:\/\/doi.org\/10.1056\/NEJMc2030164.","journal-title":"N Engl J Med"},{"key":"2647_CR59","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res: Off J Am Assoc Cancer Res. 2018;24:6175\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0758.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2647_CR60","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1172\/JCI128743","volume":"129","author":"DM Barrett","year":"2019","unstructured":"Barrett DM. Improving CAR T cell immunotherapy-mediated remissions for pediatric leukemia. J Clin Invest. 2019;129:1842\u20134. https:\/\/doi.org\/10.1172\/JCI128743.","journal-title":"J Clin Invest"},{"key":"2647_CR61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"key":"2647_CR62","doi-asserted-by":"publisher","first-page":"e002555","DOI":"10.1136\/jitc-2021-002555","volume":"9","author":"DG Tantalo","year":"2021","unstructured":"Tantalo DG, Oliver AJ, von Scheidt B, Harrison AJ, Mueller SN, Kershaw MH, et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J ImmunoTher Cancer. 2021;9:e002555. https:\/\/doi.org\/10.1136\/jitc-2021-002555.","journal-title":"J ImmunoTher Cancer"},{"key":"2647_CR63","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10:86. https:\/\/doi.org\/10.1186\/s40364-022-00434-9.","journal-title":"Biomark Res"},{"key":"2647_CR64","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3:3539\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2019000692.","journal-title":"Blood Adv"},{"key":"2647_CR65","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419\u201331. https:\/\/doi.org\/10.1038\/s41591-021-01436-0.","journal-title":"Nat Med"},{"key":"2647_CR66","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3389\/fimmu.2020.01128","volume":"11","author":"E Garc\u00eda-Guerrero","year":"2020","unstructured":"Garc\u00eda-Guerrero E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front Immunol. 2020;11:1128. https:\/\/doi.org\/10.3389\/fimmu.2020.01128.","journal-title":"Front Immunol"},{"key":"2647_CR67","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36:2267\u201380. https:\/\/doi.org\/10.1200\/JCO.2018.77.8084.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2647_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min C-K, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406536.","journal-title":"N Engl J Med"},{"key":"2647_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2026","unstructured":"Kumar S, Mateos M-V, Ye JC, Atrash S, Magen H, Quach H, et al. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med. 2026;394:51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2514752.","journal-title":"N Engl J Med"},{"key":"2647_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao W-H, Liu J, Wang B-Y, Chen Y-X, Cao X-M, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141. https:\/\/doi.org\/10.1186\/s13045-018-0681-6.","journal-title":"J Hematol Oncol"},{"key":"2647_CR71","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front Immunol"},{"key":"2647_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2326-6066.CIR-22-0095","volume":"11","author":"GM Chen","year":"2023","unstructured":"Chen GM, Chen C-H, Perazzelli J, Grupp SA, Barrett DM, Tan K. Characterization of leukemic resistance to CD19-targeted CAR T-cell therapy through deep genomic sequencing. Cancer Immunol Res. 2023;11:13\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0095.","journal-title":"Cancer Immunol Res"},{"key":"2647_CR73","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868. https:\/\/doi.org\/10.1038\/s41467-021-21177-5.","journal-title":"Nat Commun"},{"key":"2647_CR74","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01245-5.","journal-title":"Nat Med"},{"key":"2647_CR75","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020.","journal-title":"Cancer Discov"},{"key":"2647_CR76","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0146-z.","journal-title":"Nat Med"},{"key":"2647_CR77","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310. https:\/\/doi.org\/10.1182\/blood-2015-08-665547.","journal-title":"Blood"},{"key":"2647_CR78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"key":"2647_CR79","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain MD, Ziccheddu B, Coughlin CA, Faramand R, Griswold AJ, Reid KM, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140:491\u2013503. https:\/\/doi.org\/10.1182\/blood.2021015008.","journal-title":"Blood"},{"key":"2647_CR80","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652\u201363. https:\/\/doi.org\/10.1182\/blood-2018-11-883710.","journal-title":"Blood"},{"key":"2647_CR81","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1182\/bloodadvances.2024015788","volume":"9","author":"N Krasnow","year":"2025","unstructured":"Krasnow N, Maurer K, Song C, Rhoades J, Xiong K, Crnjac A, et al. Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma. Blood Adv. 2025;9:5539\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2024015788.","journal-title":"Blood Adv"},{"key":"2647_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170\u201381. https:\/\/doi.org\/10.1038\/nri2711.","journal-title":"Nat Rev Immunol"},{"key":"2647_CR83","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42:1693\u2013704. https:\/\/doi.org\/10.1038\/s41587-023-02060-8.","journal-title":"Nat Biotechnol"},{"key":"2647_CR84","doi-asserted-by":"publisher","first-page":"LB236","DOI":"10.1158\/1538-7445.AM2024-LB236","volume":"84","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xu Q, Xue L, Chen E, Liu C, Gao M, et al. Abstract LB236: Metabolically armed CD19 CAR-T cells for safe and effective treatment of relapsed or refractory CD19\u2009+\u2009B cell hematological malignancies at extremely low doses. Cancer Res. 2024;84:LB236\u2013236. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-LB236.","journal-title":"Cancer Res"},{"key":"2647_CR85","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2024-207694","volume":"144","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Fu S, Hong R, Cui J, Huang S, et al. 1\u2030 regular dose of metabolically armored CD19 CAR-T cells induces robust in vivo expansion and complete remission in relapsed or refractory diffuse large B-cell lymphoma patients. Blood Am Soc Hematol. 2024;144:2074\u20132074. https:\/\/doi.org\/10.1182\/blood-2024-207694.","journal-title":"Blood Am Soc Hematol"},{"key":"2647_CR86","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nat Nat Publishing Group. 2025;637:940\u20136. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nat Nat Publishing Group"},{"key":"2647_CR87","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.2025029532","volume":"146","author":"MB Geyer","year":"2025","unstructured":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, et al. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025;146:3163\u201374. https:\/\/doi.org\/10.1182\/blood.2025029532.","journal-title":"Blood"},{"key":"2647_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-026-01280-8","author":"K Prasad","year":"2026","unstructured":"Prasad K, Cross RS, Jenkins MR. Progress in the development of cytokine armoured CAR T cells. Nat Rev Immunol. 2026. https:\/\/doi.org\/10.1038\/s41577-026-01280-8.","journal-title":"Nat Rev Immunol"},{"key":"2647_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn DH, Mellor AL. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37:193\u2013207. https:\/\/doi.org\/10.1016\/j.it.2016.01.002.","journal-title":"Trends Immunol"},{"key":"2647_CR90","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015;125:3905\u201316. https:\/\/doi.org\/10.1182\/blood-2015-01-621474.","journal-title":"Blood"},{"key":"2647_CR91","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137:2621\u201333. https:\/\/doi.org\/10.1182\/blood.2020007445.","journal-title":"Blood"},{"key":"2647_CR92","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelg\u00e5rd G, Wenthe J, L\u00f6vgren T, Amini RM, et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24:6185\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0426.","journal-title":"Clin Cancer Res"},{"key":"2647_CR93","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med. 2022;28:1860\u201371. https:\/\/doi.org\/10.1038\/s41591-022-01960-7.","journal-title":"Nat Med"},{"key":"2647_CR94","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022;139:3708\u201321. https:\/\/doi.org\/10.1182\/blood.2021012811.","journal-title":"Blood"},{"key":"2647_CR95","doi-asserted-by":"publisher","unstructured":"Z W. J X, C Z, M Z, N X, L K, Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol. Front Immunol; 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1273507. Cited 7 Jul 2025.","DOI":"10.3389\/fimmu.2023.1273507"},{"key":"2647_CR96","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"key":"2647_CR97","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040.","journal-title":"Cancer Discov"},{"key":"2647_CR98","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"key":"2647_CR99","doi-asserted-by":"publisher","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","volume":"12","author":"JH Frenking","year":"2024","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J ImmunoTher Cancer. 2024;12:e009220. https:\/\/doi.org\/10.1136\/jitc-2024-009220.","journal-title":"J ImmunoTher Cancer"},{"key":"2647_CR100","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"2647_CR101","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"2647_CR102","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-hodgkin lymphoma. Signal Transduct Target Ther Nat Publishing Group. 2020;5:134. https:\/\/doi.org\/10.1038\/s41392-020-00256-x.","journal-title":"Signal Transduct Target Ther Nat Publishing Group"},{"key":"2647_CR103","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"key":"2647_CR104","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"2647_CR105","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98:1721\u201332. https:\/\/doi.org\/10.1007\/s00277-019-03685-z.","journal-title":"Ann Hematol"},{"key":"2647_CR106","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl. 2020;26:865\u201375. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.027.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2647_CR107","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res: CR. 2021;40:367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"2647_CR108","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"2647_CR109","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D\u2019Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158\u201372. https:\/\/doi.org\/10.1038\/s41582-021-00616-3.","journal-title":"Nat Rev Neurol"},{"key":"2647_CR110","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z.","journal-title":"Nat Rev Neurol"},{"key":"2647_CR111","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","volume":"7","author":"J Gust","year":"2023","unstructured":"Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, et al. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Adv. 2023;7:1001\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2022008119.","journal-title":"Blood Adv"},{"key":"2647_CR112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86:42\u201354. https:\/\/doi.org\/10.1002\/ana.25502.","journal-title":"Ann Neurol"},{"key":"2647_CR113","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","volume":"6","author":"F Schoeberl","year":"2022","unstructured":"Schoeberl F, Tiedt S, Schmitt A, Blumenberg V, Karschnia P, Burbano VG, et al. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv. 2022;6:3022\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021006144.","journal-title":"Blood Adv"},{"key":"2647_CR114","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41375-025-02541-6","volume":"39","author":"T Nomiyama","year":"2025","unstructured":"Nomiyama T, Setoyama D, Yamanaka I, Shimo M, Miyawaki K, Yamauchi T, et al. Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy. Leukemia. 2025;39:983\u20137. https:\/\/doi.org\/10.1038\/s41375-025-02541-6.","journal-title":"Leukemia"},{"key":"2647_CR115","doi-asserted-by":"publisher","first-page":"a022863","DOI":"10.1101\/cshperspect.a022863","volume":"5","author":"M Barker-Haliski","year":"2015","unstructured":"Barker-Haliski M, White HS. Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb Perspect Med. 2015;5:a022863. https:\/\/doi.org\/10.1101\/cshperspect.a022863.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2647_CR116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00415-025-13102-3","volume":"272","author":"F Pondrelli","year":"2025","unstructured":"Pondrelli F, Muccioli L, Mason F, Zenesini C, Ferri L, Asioli GM, et al. EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy. J Neurol. 2025;272:360. https:\/\/doi.org\/10.1007\/s00415-025-13102-3.","journal-title":"J Neurol"},{"key":"2647_CR117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/hematology.2024000534","volume":"2024","author":"MR Bishop","year":"2024","unstructured":"Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology. 2024;2024:109\u201315. https:\/\/doi.org\/10.1182\/hematology.2024000534.","journal-title":"Hematology"},{"key":"2647_CR118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1.","journal-title":"Blood Cancer J"},{"key":"2647_CR119","doi-asserted-by":"publisher","first-page":"1749587","DOI":"10.3389\/fimmu.2026.1749587","volume":"17","author":"T Schroeder","year":"2026","unstructured":"Schroeder T, Chitadze G, Dargvainiene J, Martens T, Gebauer N, Frimmel J, et al. Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: A case report. Front Immunol. 2026;17:1749587. https:\/\/doi.org\/10.3389\/fimmu.2026.1749587.","journal-title":"Front Immunol"},{"key":"2647_CR120","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","volume":"16","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Tan M, Parrondo R, Chhabra S, Dooley K, De Menezes Silva Corraes A, et al. Clinical course, risk factors and mitigating strategies for immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J Nat Publishing Group. 2025;16:18. https:\/\/doi.org\/10.1038\/s41408-025-01441-3.","journal-title":"Blood Cancer J Nat Publishing Group"},{"key":"2647_CR121","doi-asserted-by":"publisher","first-page":"e71571","DOI":"10.1002\/hsr2.71571","volume":"8","author":"AA Pillai","year":"2025","unstructured":"Pillai AA, Tiwari M, Patil SB, Gandhi D, Nanda A, Chugh S, et al. The neurocognitive impact of CAR T cell therapy in hematological cancers: A systematic review of cognitive function, quality of life, and psychological outcomes. Health Sci Rep. 2025;8:e71571. https:\/\/doi.org\/10.1002\/hsr2.71571.","journal-title":"Health Sci Rep"},{"key":"2647_CR122","doi-asserted-by":"publisher","first-page":"705","DOI":"10.21147\/j.issn.1000-9604.2025.05.04","volume":"37","author":"A Zhang","year":"2025","unstructured":"Zhang A, Zheng H, Shang Q, Yin X, Yang Y, Luo Y, et al. Can one scoring system fit all? Comparative validation of CAR-HEMATOTOX, ALL-HEMATOTOX, and eIPM for predicting immune effector cell-associated hematotoxicity following CAR-T therapy in hematologic malignancies. Chin J Cancer Res. 2025;37:705\u201317. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.05.04.","journal-title":"Chin J Cancer Res"},{"key":"2647_CR123","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","volume":"31","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, et al. Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy. Clin Cancer Res. 2025;31:4333\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1587.","journal-title":"Clin Cancer Res"},{"key":"2647_CR124","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-025-01319-4","volume":"15","author":"K Somay","year":"2025","unstructured":"Somay K, Azakli H, Chahine JJ, Loughney TM, Ozdemirli M. Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? Blood Cancer J. 2025;15:117\u201320. https:\/\/doi.org\/10.1038\/s41408-025-01319-4.","journal-title":"Blood Cancer J"},{"key":"2647_CR125","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-025-01320-x","volume":"15","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Hosoya H, Mikkilineni L, Hansen DK, Wolf JL, Lin Y. Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer J. 2025;15:112. https:\/\/doi.org\/10.1038\/s41408-025-01320-x.","journal-title":"Blood Cancer J"},{"key":"2647_CR126","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4\u2009+\u2009T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392:577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"key":"2647_CR127","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, et al. Indolent CD4\u2009+\u2009CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N Engl J Med. 2024;390:2074\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2401530.","journal-title":"N Engl J Med"},{"key":"2647_CR128","doi-asserted-by":"publisher","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther. 2023;29. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006. :438.e1-438.e16.","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"2647_CR129","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0262","author":"HK Srinagesh","year":"2025","unstructured":"Srinagesh HK, Kramer AM, Baird JH, Reschke A, Sahaf B, Cancilla J, et al. Clinical and cytokine features of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Blood Cancer Discov [Internet]. 2025. https:\/\/doi.org\/10.1158\/2643-3230.BCD-25-0262. [cited 2026 Jan 18].","journal-title":"Blood Cancer Discov [Internet]"},{"key":"2647_CR130","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: Characteristics, management, and future directions. j allergy clin immunol pract. 2022;10:460\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2021.10.037.","journal-title":"j allergy clin immunol pract"},{"key":"2647_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656108","author":"Y Ke","year":"2025","unstructured":"Ke Y, Zhou F. Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: A systematic review. Front Immunol [Internet] Front. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1656108. [cited 2026 Jan 19];16.","journal-title":"Front Immunol [Internet] Front"},{"key":"2647_CR132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131:121\u201330. https:\/\/doi.org\/10.1182\/blood-2017-07-793760.","journal-title":"Blood"},{"key":"2647_CR133","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial. Mol Ther Elsevier. 2024;32:3821\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009.","journal-title":"Mol Ther Elsevier"},{"key":"2647_CR134","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"key":"2647_CR135","doi-asserted-by":"publisher","first-page":"217083","DOI":"10.1016\/j.canlet.2024.217083","volume":"597","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhang G, Xu Y, Yang S, Wang J, Li Z, et al. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the sphinx? Cancer Lett. 2024;597:217083. https:\/\/doi.org\/10.1016\/j.canlet.2024.217083.","journal-title":"Cancer Lett"},{"key":"2647_CR136","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med Nat Publishing Group. 2024;30:984\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02826-w.","journal-title":"Nat Med Nat Publishing Group"},{"key":"2647_CR137","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood.2021010813","volume":"138","author":"DC Bishop","year":"2021","unstructured":"Bishop DC, Clancy LE, Simms R, Burgess J, Mathew G, Moezzi L, et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood. 2021;138:1504\u20139. https:\/\/doi.org\/10.1182\/blood.2021010813.","journal-title":"Blood"},{"key":"2647_CR138","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","volume":"12","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-hodgkin lymphoma. Blood Cancer J. 2022;12:113. https:\/\/doi.org\/10.1038\/s41408-022-00707-4.","journal-title":"Blood Cancer J"},{"key":"2647_CR139","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood.2024025828","volume":"144","author":"J Hu","year":"2024","unstructured":"Hu J, Dunbar CE. T-cell lymphomas in recipients of CAR-T cells: Assessing risks and causalities. Blood. 2024;144:2473\u201381. https:\/\/doi.org\/10.1182\/blood.2024025828.","journal-title":"Blood"},{"key":"2647_CR140","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","volume":"33","author":"A Cadinanos-Garai","year":"2025","unstructured":"Cadinanos-Garai A, Flugel CL, Cheung A, Jiang E, Vaissi\u00e9 A, Abou-El-Enein M. High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing. Mol Ther: J Am Soc Gene Ther. 2025;33:2291\u2013309. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.006.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"2647_CR141","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1038\/s41467-025-59298-w","volume":"16","author":"G Cao","year":"2025","unstructured":"Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, et al. Two-stage CD8\u2009+\u2009CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun Nat Publishing Group. 2025;16:4205. https:\/\/doi.org\/10.1038\/s41467-025-59298-w.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"2647_CR142","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1038\/s41467-025-59904-x","volume":"16","author":"G Cheloni","year":"2025","unstructured":"Cheloni G, Karagkouni D, Pita-Juarez Y, Torres D, Kanata E, Liegel J, et al. Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire. Nat Commun Nat Publishing Group. 2025;16:4819. https:\/\/doi.org\/10.1038\/s41467-025-59904-x.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"2647_CR143","doi-asserted-by":"publisher","unstructured":"Storci G, De Felice F, Ricci F, Santi S, Messelodi D, Bertuccio SN et al. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells. J Clin Invest 134:e173096. https:\/\/doi.org\/10.1172\/JCI173096","DOI":"10.1172\/JCI173096"},{"key":"2647_CR144","doi-asserted-by":"publisher","first-page":"1378944","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L, Jan\u017ei\u010d L, Ihan A, Kopitar AN. Biomarkers for prediction of CAR T therapy outcomes: Current and future perspectives. Front Immunol. 2024;15:1378944. https:\/\/doi.org\/10.3389\/fimmu.2024.1378944.","journal-title":"Front Immunol"},{"key":"2647_CR145","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO-24-01933","volume":"43","author":"FL Locke","year":"2025","unstructured":"Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, et al. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: Phase I experience from the ALPHA2\/ALPHA clinical studies. J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43:1695\u2013705. https:\/\/doi.org\/10.1200\/JCO-24-01933.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2647_CR146","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","volume":"43","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhou Y, Yu J, Kim YJ, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025;43:329\u201344. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"key":"2647_CR147","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.medj.2025.100804","volume-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Li Z, Zhu Y, Li M, Chen Y, Lee D, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Volume 6. New York, N.Y.: Med; 2025. p. 100804. https:\/\/doi.org\/10.1016\/j.medj.2025.100804."},{"key":"2647_CR148","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Volume 388. New York, N: Science; 2025. pp. 1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473."},{"key":"2647_CR149","doi-asserted-by":"publisher","first-page":"e011759","DOI":"10.1136\/jitc-2025-011759","volume":"13","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, van Diest E, Murphy DE, Ashoti A, Evers MJW, Narayanavari SA, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J ImmunoTher Cancer. 2025;13:e011759. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J ImmunoTher Cancer"},{"key":"2647_CR150","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet Lond Engl. 2025;406:228\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(25)01030-X.","journal-title":"Lancet Lond Engl"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02647-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T22:46:34Z","timestamp":1779835594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02647-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02647-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}